Targeting the regulation of MARCH5 and Akt pathways, either independently or in combination, could offer a novel therapeutic strategy for the treatment of pathological cardiac hypertrophy and even cardiac insufficiency. The gene discussed is MARCHF5; the disease is heart failure.